Pembrolizumab/Lenvatinib Combo Tops Week in Review

Article

Top news of the day from across the health care landscape.

5. NASP 2019: A Doctor's Perspective on Specialty Pharmacy

The annual National Association of Specialty Pharmacy annual meeting shed light on the significant role these caregivers play in patient care. Read more.

4. Ofatumumab Demonstrates Efficacy in Relapsing Multiple Sclerosis

Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis. Read more.

3. Certain BRAF Mutations in Colorectal Cancer May Respond to Anti-EGFR Therapy

Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment. Read more.

2. Novel Hemophilia A Treatment Method Sees Early Success

New approach involves treating patients with a high dose factor VIII concentrates along with emicizumab, a modification of the standard immune tolerance induction. Read more.

1. FDA OKs Pembrolizumab/Lenvatinib Combo for Advanced Endometrial Carcinoma

The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada. Read more.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.